**PFIZER-BIONTECH COVID-19 VACCINATION SCHEDULE AND DOSING**

**FOR NON-IMMUNOCOMPROMISED POPULATIONS**

**Pfizer-BioNTech**

**Ages 6 months – 4 years**

dose/injection volume (dilute before use)

*Maroon Cap*

**Dose 1**

**Primary**

DOSE 1

3 μg/0.2 mL

In 3-8 weeks

**Dose 2**

**Primary**

DOSE 2

3 μg/0.2 mL

**Dose 3**

**Primary**

DOSE 3

3 μg/0.2 mL

**In at least 8 weeks**

**Pfizer-BioNTech**

**Ages 5 years – 11 years**

dose/injection volume (dilute before use)

*Orange Cap*

**Dose 1**

**Primary**

DOSE 1

10 μg/0.2 mL

In 3-8 weeks

**Dose 2**

**Primary**

DOSE 2

10 μg/0.2 mL

**Dose 3**

**Primary**

DOSE 3

10 μg/0.2 mL

**In at least 5 months**

**Pfizer-BioNTech**

**Ages 12 years and older**

dose/injection volume (Do NOT dilute before use)

*Gray Cap*

**Dose 1**

**Primary**

DOSE 1

30 μg/0.3 mL

In 3-8 weeks

**Dose 2**

**Primary**

DOSE 2

30 μg/0.3 mL

**Dose 3**

**Primary**

DOSE 3

30 μg/0.3 mL

**In at least 5 months**

**Dose 4**

**Booster**

DOSE 4

30 μg/0.3 mL

**In at least 4 months**

* People ages 50 years and older should get a 2nd booster.

---

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose. Any COVID-19 vaccine product (age appropriate) may be administered for a booster dose. It does not need to be the same product used for the primary series.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months – 64 years, especially for males ages 12–39 years. Source: CDC.

See the Pfizer-BioNTech COVID-19 Vaccine Guidance for children who are transitioning from a younger to older age group during their vaccination window.